NCT00569127 2026-03-18
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Advanced Accelerator Applications
Grupo Espanol de Tumores Neuroendocrinos
Montefiore Medical Center
Radiomedix, Inc.
Ipsen
Ipsen
Ipsen
Advanced Accelerator Applications
Novartis
Philipps University Marburg